La Jolla Pharmaceutical preclinical data

In a mouse model of non-alcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC), thrice-weekly 25 mg/kg IV GCS-100 significantly reduced liver fibrosis, improved non-alcoholic fatty liver diseas...